Goldman Sachs analyst Corinne Johnson started Fulcrum Therapeutics (FULC) with an Early-Stage Biotech rating.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $6 from $2 at BofA
- Cautious Outlook on Fulcrum Therapeutics Amid Safety Concerns and Narrowed Trial Focus
- Fulcrum Therapeutics Elects New Directors at Annual Meeting
- Fulcrum Therapeutics price target raised to $9 from $6 at Piper Sandler
- Stocks slide as Trump threatens new tariffs against EU and Apple: Morning Buzz